Neuronetics STIM shares are trading higher on Tuesday after BTIG reiterated a Buy rating on the stock and raised its price target from $6 to $10.
Neuronetics is a commercial-stage medical technology company. It is focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.
Neuronetics shares traded up 13.73% to $5.88 on Tuesday. The stock has a 52-week high of $9.39 and a 52-week low of $1.25.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
